Research People and Projects

This I-Corps project is based on the development of a pharmacological adjuvant that limits the abuse liability of stimulant medications. The proposed technology may be used to develop a new class of medications with low or no abuse liability. Data collected to date indicate that the technology also can enhance the therapeutic efficacy of stimulant medications for some indications. In addition, proof-of-concept studies indicate that the proposed adjuvant can be co-formulated with stimulants and opioids without affecting their stability, providing a platform technology that may be readily applied to improve the safety profile of many existing medications. The proposed technology may have applications to enhance the safety and tolerability for treatment with stimulant medications for a range of psychiatric and neurological indications.